peoplePerson
Alexander Drilon
Led the trials of larotrectinib, entrectinib, repotrectinib and selpercatinib that turned rare gene fusions into treatable targets.
Runs MSK's early drug development service. Lead author on the pivotal NTRK-fusion larotrectinib and ROS1/NTRK repotrectinib studies and a leader of the LIBRETTO RET programme.
Role
Chief, Early Drug Development Service
Institution
Specialisms
Oncogene-driven lung cancerNTRK, ROS1, RET fusionsPhase 1 trials
Profiles
| Title | Journal | Year |
|---|---|---|
| Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children | New England Journal of Medicine | 2018 |
| Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer | New England Journal of Medicine | 2024 |